Category: News


MRA's Latest Research Report: The Melanoma Research Community Reunites

11 August 2022 In Allies & Partnerships, Events, Melanoma Stories, News, Prevention, Science, Treatment

Each year, MRA brings together hundreds of people from across the melanoma research community to exchange ideas, report on scientific progress, celebrate achievements, and mourn our collective losses.

Read More


New Funding Alert: Department of Defense Melanoma Research Program

1 July 2022 In Allies & Partnerships, News, Science

Research Funding Alert: The Department of Defense Melanoma Research Program will award up to $40 million in funding for melanoma research in FY22. Learn more about funding mechanisms, focus area, and deadlines!

Read More


Leveraged Finance & Private Equity Communities Unite to Raise Record $3 Million for Melanoma Research

21 June 2022 In Allies & Partnerships, Events, News, Prevention

On Thursday, June 16, 2022, more than 900 people from over 100 firms from the leveraged finance and private equity communities came together for the Leveraged Finance Fights Melanoma (LFFM) benefit and cocktail party. Hosted at the Museum of Modern Art, the event raised a record breaking $3 million for the Melanoma Research Alliance’s (MRA) mission to advance the world’s most innovative and promising melanoma research.

Read More


MRA Announces $13 Million in Grants to Advance Melanoma Prevention, Detection & Treatment

By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 19 May 2022 In News, Prevention, Science, Treatment

Coinciding with Melanoma Awareness Month, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced funding for 27 research grants totaling $13,046,774 to support new research aimed at advancing melanoma prevention, diagnosis and treatment.

Read More


The Melanoma Research Alliance Names Dr. Marc Hurlbert as Chief Executive Officer

11 May 2022 In Allies & Partnerships, News

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced that its Board of Directors appointed Marc Hurlbert, PhD, as its new Chief Executive Officer.

Read More


A Message from the Melanoma Research Alliance

21 April 2022 In News

Michael Kaplan, MRA’s President & CEO, will retire on April 30, 2022. Kaplan, who has led the Melanoma Research Alliance since 2016, will be succeeded by Dr. Marc Hurlbert.

Read More


Unlocking the Potential of Localized Treatments By Better Understanding Treatment Response

By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 March 2022 In News, Science, Treatment

It’s easy to think of melanoma – or any cancer – in black and white terms. You have it or you don’t, it responds or it’s resistant to treatment, or it grows or it shrinks. However, like most things, the reality is far more complex.

Read More


MRA Applauds Approval of Relatlimab + Nivolumab for the Treatment of Advanced Melanoma

18 March 2022 In News, Science, Treatment

The Melanoma Research Alliance (MRA) welcomed the news today that the U.S. Food & Drug Administration (FDA) has approved Opdualag™, Bristol-Myers Squibb’s new combination immunotherapy for the treatment of advanced melanoma.

Read More


Recordings from MRA's 2022 Patient Forum

16 March 2022 In Allies & Partnerships, Events, Melanoma Stories, News, Policy, Prevention, Science, Treatment

MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, 2022, brought together hundreds of melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.

Read More


New Research Says Immunotherapy Should be First-Line Therapy for Patients with BRAF-Mutant Melanoma

By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 2 February 2022 In News, Science, Treatment

While all patients with advanced melanoma can be treated with checkpoint immunotherapies, patients with tumors containing the BRAF mutation can also be treated with targeted therapies. However, until now, doctors have had little prospective data to determine which treatment approach should be started first. A new study led by Dr. Michael Atkins provides practice-changing insight.

Read More


Login

×